文献詳細
特集 ここが知りたい! 筋層非浸潤性膀胱癌─エキスパートが答える日常診療の疑問点
〈診断〉
文献概要
質問 : NMIBCの治療方針を決める際に,どのようなリスク分類を使用すればよいですか?
▶ポイント
・臨床病理学的な6項目からなるEORTCの分類とBCG施行群におけるCUETOの分類が標準的なリスク分類である.
・上記分類でも高リスク群の予後予測は難しく,さまざまな予後因子が研究されている.
・分子生物学的な観点からも新しい膀胱癌の分類が進められている.
▶ポイント
・臨床病理学的な6項目からなるEORTCの分類とBCG施行群におけるCUETOの分類が標準的なリスク分類である.
・上記分類でも高リスク群の予後予測は難しく,さまざまな予後因子が研究されている.
・分子生物学的な観点からも新しい膀胱癌の分類が進められている.
参考文献
1) 日本泌尿器科学会(編) : 膀胱癌診療ガイドライン2015年版. 医学図書出版, 東京, 2015
2) http://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-2015-v1.pdf
3) http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
4) Sylvester RJ, van der Meijden APM, Oosterlinck W, et al : Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables : a combined analysis of 2596 patients from seven EORTC trials. Euro Urol 49 : 465─466 ; discussion 475─477, 2006
5) http://www.eortc.be/tools/bladdercalculator/
6) Fernandez-Gomez J, Madero R, Solsona E, et al : Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin : the CUETO Scoring Model. J Urol 182 : 2195─2203, 2009
7) http://www.aeu.es/Cueto.html
8) Xylinas E, Kent M, Kluth L, et al : Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. British Journal of Cancer 109 : 1460─1466, 2013
9) Palou J, Sylvester RJ, Faba OR, et al : Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Euro Urol 62 : 118─125, 2012
10) Cho KS, Seo HK, Joung JY, et al : Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 182 : 2625─2630, 2009
11) Golijanin D, Yossepowitch O, Beck SD, et al : Carcinoma in a bladder diverticulum : presentation and treatment outcome. J Urol 170 : 1761─1764, 2003
12) Bishr M, Lattouf J-B, Latour M, et al : Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J 8 : E306─E310, 2014
13) Palou J, Rodríguez-Rubio F, Millán F, et al : Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urol 73 : 1313─1317, 2009
14) Rouprêt M, Seisen T, Compérat E, et al : Prognostic interest in discriminating muscularis mucosa invasion(T1a vs T1b)in nonmuscle invasive bladder carcinoma : French national multicenter study with central pathology review. J Urol 189 : 2069─2076, 2013
15) Knowles M and Hurst CD : Molecular biology of bladder cancer : new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15 : 25─41, 2015
16) Sjodahl G, Lauss M, Lovgren K, et al : A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18 : 3377─3386, 2012
17) Damrauer JS, Hoadley KA, Chism DD, et al : Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc of the Natl Acad Sci USA 111 : 3110─3115, 2014
18) Choi W, Porten S, Kim S, et al : Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer cell 25 : 152─165, 2014
19) Cancer Genome Atlas Research Network : Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 : 315─322, 2014
20) Aine M, Eriksson P, Liedberg F, et al : On Molecular Classification of Bladder Cancer : Out of One, Many. Eur Urol 68 : 921─923, 2015
21) van Kessel KE, Zuiverloon TC, Alberts AR, et al : Targeted therapies in bladder cancer : an overview of in vivo research. Nat rev Urol 12 : 681─694, 2015
22) Miyamoto H, Yang Z, Chen Y-T, et al : Promotion of bladder cancer development and progression by androgen receptor signals. Journal of the National Cancer Institute 99 : 558─568, 2007
23) Li Y, Izumi K and Miyamoto H : The role of the androgen receptor in the development and progression of bladder cancer. Japanese journal of clinical oncology 42 : 569─577, 2012
24) Izumi K, Taguri M, Miyamoto H, et al : Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 5 : 12665─12674, 2014
掲載誌情報